An abnormal hyperresponse of GH to intravenous injection of TRH in a 66-year-old female pellagra patient with typical 3'D's was reported. Diagnosis of pellagra was mainly based on her clinical course and manifestations, although serum levels of nicotinic acid and serotonin were within the normal range. Serum vitamin A and B2 levels were low. However, these findings did not exclude the diagnosis. The abnormal GH response to TRH observed in this patient was decreased at 2 months and thoroughly disappeared at 10 months after admission. GH response to arginine showed an exaggerated and sustained response on admission, decreased at 2 months and showed an almost normal pattern at 10 months after admission. TSH and prolactin response to TRH were normal throughout the clinical course. LH and FSH response to LH-RH were exaggerated, suggesting post-menopausal hypogonadism. Cortisol response to ACTH showed slightly sustained reactions at both times of the provocation.
Although it is well known that thyrotropin releasing hormone (TRH) stimulates both thyrotropin (TSH) and prolactin (PRL) release from the anterior pituitary in normal subjects (Anderson et al., 1971 ; Bowers et al., 1971 ; Jacobs et al., 1971) , it also has been reported that in some pathological conditions such as acromegaly or gigantism (Irie and Tsushima, 1972 ; Schalch et al., 1972; Faglia et al., 1973) , primary hypothyroidism (Hamada et al., 1976) , anorexia nervosa (Maeda et al., 1976) , mental depression (Maeda et al., 1975) , chronic liver diseases (Panerai et al., 1977) , alcoholic hepatitis with cirrhosis (Zanboni and ZanboniMuciaccia, 1977) , liver cancer (Kamijo et al., 1980) , chronic renal failure (GonzalezBarcena et al., 1973; Hasegawa et al., 1975) , insulin dependent diabetes mellitus (Ceda et al., 1982) , and isolated TSH deficiency (Miyai et al., 1976) , TRH is able to stimulate growth hormone (GH) release.
Recently, we studied a patient with pellagra whose GH release from the pituitary was abnormally stimulated by TRH administration. This paper deals with some endocrinological aspects of a pellagra patient with severe psychiatric disturbance. The patient was discharged at 4 months after admission. As a multivitamin preparation, PanvitanR (Takeda Chemical Industries, Co., Osaka, Japan) was used. This preparation contains 15 mg of nicotinic acid per each gram. the abnormal but also the normal GH releasing mechanism was stimulated in this patient. It has been reported that TRH has no significant influence on GH release in normal subjects, but has a stimulatory influence in some pathological conditions such as cited above. Pellagra with clinically typical manifestations including psychiatric disturbance should be added to these conditions.
One may suppose that this is a case of a patient with protein calorie malnutrition and multiple vitamin deficiency who exhibited. a ' paradoxical' GH response to TRH injection. However, total protein in the serum was almost within the normal range. This is probably related to taking soybean protein to some extent. As Dickerson and Wiryanti (1978) mentioned, pellagra should be considered as a complex of metabolic disorders. The etiology of the disease is complicated and there is some doubt as to whether the human disease is a pure nicotinic acid deficiency. These support the finding that the abnormal hyperresponse of GH to TRH observed in this patient is due to pellagra. Althoug both nicotinic acid and serotonin levels in the serum were within the normal range, these normal levels did not exclude pellagra. Vitamin A and B2 levels in the serum were low. It is not possible to definitely determine whether the ' paradoxical' GH response in this patient is caused only by nicotinic acid rather than multiple vitamin deficiency. It would have been necessary to have treated this patient solely with nicotinamide to decide this issue clearly.
The mechanism of TRH-induced GH release in this patient is considered to be due to (1) the abnormality in the GH secreting cell with altered cellular receptors, (2) the abnormality of the GH secreting mechanism at the level of hypothalamus or at the higher level in the central nervous system. GH increase in this patient was observed 15 min. after the TRH injection, just as observed in acromegaly (Irie and IEIRI et al. Endocrinol. Japon. August 1984 Tsushima, 1972) . This seems to indicate that the GH secreting abnormality in this patient was present at the level of the pituitary. However, changes in the celullar receptors such as acromegaly is unlikely in this patient.
In mental depression and anorexia nervosa, in which impaired GH response to usual challenges (Sacher et al., 1972) and non-specific release of GH by TRH (Maeda et al., 1975; Maeda et al., 1976) are present, a disturbance of brain serotonin (Ashhcroft et al., 1966; Shaw et al., 1967) and/or brain catecholamine (Barry and Klawans, 1976) metabolism has been suspected. GH responses to insulin induced hypoglycemia in the depression was significantly less than that in normal subjects, suggesting the normal GH releasing mechanism is at least not enhanced (Maeda et al., 1975) .
In hepatic failure, a disturbance of brain serotonin turnover due to an increased passage of tryptophan from the plasma into the brain has been postulated (Munro et al., 1975) .
In insulin dependent diabetics, it has been reported that GH paradoxically responds to TRH injection (Ceda et al., 1982) . However, this response was not so obvious as the reaction of GH to TRH observed in this patient. There are some patients with non-insulin dependent diabetes, who exhibited a 'paradoxical' GH response to TRH (Ieiri et al., unpublished data) . In these patients, there is a significant negative correlation between the net increase in GH after TRH and arginine injection (Ieiri et al., unpublished data) .
In renal failure, a decrease in TSH and/ or TRH clearance may contribute to the sustained elevation in serum GH levels after TRH administration (Gonzalez-Barcena et al., 1973) . However, decreased clearance as a cause of increased GH levels after TRH in this patient was unlikely since no sign of renal failure was observed.
Estrogens may be an another cause of hyperresponse of GH to TRH. Carlson et al. (1973) reported that the basal level of GH was increased after a treatment with diethylstilbestrol in man, but GH response to TRH was not altered by the treatment. The serum estrogen level was not examined in this patient, but the estrogen level in this patient was considered to be below the normal level, since LH and FSH responses to LH-RH were high and exaggerated as usually seen in postmenopausal women. has been calculated on admission: 0.74; after admission: 1.1 4, respectively in Prinsloo's report (Pronsloo et al., 1971b) . The index in this patient was 0.17 on admission and 0.14 two months after admission, showing a lower value than that in Prinsloo's report. In summary, an abnormal hyperresponse of GH to TRH in a pellagrin was described. This is probably due to some changes in GH secreting mechanism in the hypothalamus or the higher levels in the central nervous system. These changes in the GH secreting mechanism resemble those reported previously in depression, anorexia nervosa, liver diseases and diabetes mellitus. However, it seems that the mechanism(s) responsible for the abnormal GH response to TRH observed in this patient is different at least partially from that of disorders reported previously, in which TRH is able to stimulate GH secretion. 
